Actively Recruiting
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2025-11-21
495
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
Sponsors
C
Changchun GeneScience Pharmaceutical Co., Ltd.
Lead Sponsor
H
Henan Cancer Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.
CONDITIONS
Official Title
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically and/or cytologically confirmed malignancy.
- Age 18 years or older at enrollment.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of 3 months or more.
- Meeting the diagnostic criteria for cachexia based on Fearon's criteria.
- Body mass index (BMI) of 30 or less.
You will not qualify if you...
- Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting.
- Patients receiving tube feeding or parenteral nutrition.
- Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.
- Patients with acquired immunodeficiency syndrome (AIDS).
- Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.
- Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital, Affiliated to Zhengzhou University
Zhengzhou, Henan, China, 45000
Actively Recruiting
Research Team
S
Suxia Luo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here